Core Viewpoint - The company is experiencing a decline in revenue and net profit for 2024, with expectations for improvement driven by cost control and AI integration in the future [1][2][3] Financial Performance - 2024 revenue, net profit attributable to parent, and net profit excluding non-recurring items are projected at 38.67 billion, -9.03 billion, and -9.19 billion respectively, showing year-on-year declines of -11.1%, -1072%, and -1091% [1] - For Q1 2025, revenue, net profit attributable to parent, and net profit excluding non-recurring items are expected to be 6.72 billion, -0.53 billion, and -0.63 billion respectively, with year-on-year declines of -18%, -525%, and -2879% [1] - The 2024 performance aligns with expectations, but Q1 2025 shows increased pressure on net profit growth due to extended customer payment cycles and rising expense ratios [1] Business Segments - The reproductive health business in 2024 saw a revenue decline of 2.5% year-on-year, totaling 11.49 billion, influenced by fertility rates and testing prices [1] - The company is expanding its first and third-level prevention services, with notable revenue growth in carrier screening (+12.3%), chromosome abnormality detection (+2.4%), newborn genetic disease screening (+47.4%), and hereditary disease testing (+53.1%) [1] - Revenue from tumor and chronic disease prevention in 2024 reached 6.25 billion, reflecting a stable growth of 19.0% year-on-year, driven by government collaboration and industry-academia cooperation [1] Multi-Omics and Precision Medicine - Multi-omics big data service revenue in 2024 was 6.67 billion, down 5.6% year-on-year, primarily due to international geopolitical factors affecting the Americas [2] - Precision medicine revenue for 2024 was 13.29 billion, also down 5.6% year-on-year, largely due to a significant decline in COVID-related revenue; excluding this, the revenue grew by 22.4% year-on-year [2] Expense and Profitability Metrics - In 2024, the sales, management, R&D, and financial expense ratios were 26.12%, 10.59%, 15.68%, and -1.30%, showing increases of 2.29, 1.42, 3.52, and a decrease of 0.25 percentage points year-on-year [2] - For Q1 2025, these ratios were 24.22%, 11.02%, 17.46%, and -4.09%, with year-on-year changes of +3.53, -1.11, +4.51, and -2.85 percentage points [2] - The gross profit margins for 2024 and Q1 2025 were 41.47% and 43.55%, reflecting declines of 8.43 and 5.65 percentage points year-on-year, attributed to lower margins in certain business segments [2] Future Outlook - The company has adjusted its revenue expectations for the reproductive health business downward while increasing projections for sales and R&D expense ratios [3] - Revenue forecasts for 2025-2027 are set at 42.6 billion, 47.4 billion, and 52.6 billion, with net profit attributable to parent at 0.28 billion, 0.76 billion, and 1.01 billion respectively [3] - The company maintains a target price of 52.19, reflecting a 5.1x price-to-sales ratio for 2025, consistent with industry averages [3]

Group 1: Industry Trends and Challenges - The third-party testing and gene sequencing service sectors are experiencing a decline in performance due to decreased demand and other factors [1][2] - The complexity and high costs associated with gene sequencing compared to traditional testing methods are hindering industry growth [1][2] Group 2: Company Strategies and Innovations - BGI has implemented high-throughput sequencing automation and launched the GenSIRO localized solution to enhance laboratory efficiency [2] - The company introduced the GeneT AI model in September 2024 to accelerate genomic report interpretation, significantly improving operational efficiency [2] Group 3: Market Opportunities - Non-invasive prenatal genetic testing has seen increased coverage and penetration, particularly in provinces like Hebei, Jiangsu, and Guangdong, indicating potential for future business expansion [2] - The tumor prevention and chronic disease management sectors present substantial market potential, with BGI focusing on early screening and comprehensive health management strategies [3] Group 4: Financial Performance and Projections - BGI's gross margin has declined due to increased market competition and external factors such as medical insurance cost control [4] - The company plans to enhance product development and optimize its product matrix to improve gross margins in the future [4] Group 5: International Business Development - BGI's joint venture Genalive secured a 950 million RMB order for outsourced testing services in Saudi Arabia, marking a significant achievement in international operations [4] - The company is actively expanding its overseas business through partnerships and technology transfer projects in various countries [4] Group 6: Product Development and Health Management - BGI has developed a comprehensive colorectal cancer screening product with high sensitivity and specificity, achieving over 2.12 million tests completed [7] - The i99 health management system, launched in April 2025, utilizes AI to provide customized health management solutions, marking a shift towards proactive health care [10][11] Group 7: Future Outlook - BGI is undergoing a strategic transition to address industry pain points and enhance automation and intelligence in its operations [12] - The company aims to leverage its core technology to expand into precision health management, thereby increasing service value and business boundaries [13]

Core Insights - The company, BGI Genomics, reported a significant decline in its financial performance for 2024, with a net profit loss of 903 million yuan, marking its first annual net loss since its listing and the largest loss to date [1][2] Financial Performance - BGI Genomics achieved a revenue of 3.867 billion yuan in 2024, a year-on-year decrease of 11.10% [1] - The net profit attributable to shareholders was a loss of 903 million yuan, representing a staggering year-on-year decline of 1071.68% [1][2] - The company's net profit had peaked at 2.09 billion yuan in 2020, but has been on a downward trend since, with profits of 1.462 billion yuan in 2021, 803 million yuan in 2022, and 93 million yuan in 2023 [2] - Total assets decreased to 12.542 billion yuan, down 7.87% year-on-year, while net assets attributable to shareholders fell to 9.135 billion yuan, a reduction of 7.35% [2] Business Segment Performance - The infection prevention business saw a dramatic revenue drop of 85.91%, with earnings of only 73 million yuan in 2024 compared to 516 million yuan in 2023 [3] - Despite the downturn in the infection prevention segment, the reproductive health and oncology businesses maintained growth, with the precision medicine testing solutions segment showing a 22.37% increase when excluding the impact of public health events [3] Industry Outlook - The global genetic testing market is projected to grow from 19.66 billion USD in 2024 to 32.83 billion USD by 2029, with a compound annual growth rate of 10.81% [4] - The company plans to increase investments in medical AI models, intelligent testing platforms, and integrated multi-omics technologies to enhance its core competitiveness and adapt to market changes [4]

Core Viewpoint - The balance between technological idealism and commercial reality is crucial for BGI Genomics, which aims to leverage financial metrics to measure the potential of genomics [1][15]. Financial Performance - BGI Genomics reported a revenue of 3.87 billion yuan in 2024, a decline of 11.10% compared to 4.35 billion yuan in 2023 [4][3]. - The company experienced its first net loss since its IPO, with a net profit attributable to shareholders of -902.69 million yuan, a staggering decrease of 1071.68% from a profit of 92.90 million yuan in 2023 [4][5]. - The weighted average return on equity (ROE) fell to -9.50%, down 10.43 percentage points from 0.93% in the previous year [12][13]. Business Segment Analysis - Revenue from the largest segment, precision medical testing solutions, decreased by 5.57% to 1.33 billion yuan [7][8]. - The second-largest segment, reproductive health services, saw a revenue drop of 2.46% to 1.15 billion yuan [7][8]. - The multi-omics big data services and synthesis business generated 667 million yuan, down 5.64% [7][8]. - Despite overall revenue decline, some segments like tumor and chronic disease prevention services showed growth, but their contribution to total revenue remains limited [7]. Cost and Profitability Metrics - Overall gross margin decreased by 8.43 percentage points to 41.47%, while operating expenses increased, with sales expenses rising to 26.12% [9][11]. - The net profit margin plummeted from 2.14% to -23.34%, influenced by rising costs and intensified price competition [11][12]. - Asset impairment losses surged to -2.42 billion yuan in 2024, more than three times the previous year's losses, indicating the impact of aggressive past business strategies [11][12]. Strategic Initiatives - BGI Genomics introduced the "i99 Smart Health" system, integrating various health assessments and aiming to capture a share of the chronic disease management market, projected to exceed 1.8 trillion yuan in 2024 [14][15]. - The company faces challenges in convincing the middle class to invest in advanced health management services, given the high pricing compared to traditional health check-ups [14][15]. - To achieve profitability, BGI may need to restructure its business model, including optimizing laboratory operations and exploring data asset monetization [15].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].

Core Viewpoint - The concept of "self-controllable + domestic substitution" is emerging as a clear value anchor in the capital market amid global industrial chain restructuring and intensified technological competition. Companies with foundational innovation capabilities are demonstrating resilience through cycles [1]. Group 1: Company Performance - BGI Genomics reported a revenue of 3.867 billion yuan for the fiscal year 2024, showcasing its leadership in the global gene technology industry with comprehensive coverage of the entire industry chain and application scenarios [1]. - In the field of reproductive health, despite a declining birth rate, BGI Genomics achieved a year-on-year revenue growth of approximately 47.38% in newborn genetic disease screening and about 53.13% in clinical diagnosis of genetic diseases [2]. Group 2: Market Expansion and Strategy - The company has established a three-tier prevention system for birth defects covering pre-marital, pre-pregnancy, pregnancy, newborn, and childhood stages, successfully implementing prenatal screening and birth defect detection services in various cities [2]. - BGI Genomics is actively expanding its product layout and optimizing costs, extending genetic testing from secondary prevention to primary and tertiary prevention, thereby increasing market penetration and opening up new market spaces [2]. Group 3: Growth in Cancer and Chronic Disease Prevention - Significant growth was observed in the cancer and chronic disease prevention sectors, with colorectal cancer testing showing a remarkable year-on-year growth rate of 270.60% [3]. - The domestic high-throughput gene testing market for cancer reached a scale of 4.1 billion yuan in 2021, projected to grow to 49.1 billion yuan by 2030, with a CAGR of 32% from 2022 to 2030 [3]. Group 4: Technological Innovation and AI Integration - BGI Genomics has developed a differentiated layout in the AI + healthcare sector, utilizing AI technology to reconstruct the value chain of genetic testing [9]. - The company has launched the GeneT intelligent analysis system, significantly improving the efficiency of genetic variant interpretation, and established the ChatGeneT platform for public genetic health management [10]. Group 5: Strategic Advantages and Future Outlook - BGI Genomics leverages its technological foundation to create a comprehensive product matrix covering reproductive health, cancer screening, chronic disease prevention, and infection control, enhancing service accessibility through large-scale testing [7]. - The integration of hard technology and soft power through AI-driven innovations is expected to unlock dual benefits of increased healthcare spending and health consumption upgrades, positioning the company favorably in the market [12].

华大基因表示，业绩下滑主要受整体营收规模下降、产品结构调整、信用减值损失扩大、资产减值准备 计提增加、研发投入上升以及固定资产运营成本增长等六大因素影响。其中，报告期内信用减值损失达 1.96亿元，资产减值损失2.42亿元，经营活动现金流净额同比下滑76.58%。 截至2024年末，华大基因总资产125.42亿元，同比下降7.87%；归属于母公司股东的净资产下降至91.35 亿元，同比减少7.35%。流动性趋紧叠加资产减值压力释放，使得全年财务表现承压，尤其四季度单季 亏损进一步扩大。 从主营业务结构看，各板块业绩表现分化明显。生育健康、肿瘤与慢病防控业务整体维持增长态势，但 感染防控业务受突发公共卫生事件影响遭遇重挫，成为拉低整体收入的重要因素之一。 4月26日，华大基因（300676.SZ）发布2024年年度报告及财务报告。数据显示，受行业周期调整、市场 竞争加剧及突发公共卫生事件影响等多重因素叠加，公司全年业绩大幅承压，净利润由盈转亏。 | | | | | 本年末比上年 | | 1.80 | | --- | --- | --- | --- | --- | --- | --- | | | 2024 年末 ...

深圳华大基因股份有限公司 2024 年度监事会工作报告 深圳华大基因股份有限公司 2024 年度监事会工作报告 2024 年度，深圳华大基因股份有限公司（以下简称公司）监事会严格按照 《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以 下简称《证券法》）等法律法规和《公司章程》《监事会议事规则》等相关规定， 本着对全体股东负责的态度，认真勤勉履行监督职责，依法独立行使监事会职权， 通过召开监事会会议、出席股东大会及列席董事会，对公司重大经营事项决策程 序、经营活动、财务状况、公司董事与高级管理人员履行职责情况等重大事项进 行了有效监督，促进公司规范运作和健康发展，维护了公司利益和全体股东的合 法权益。现将公司监事会 2024 年度履职情况报告如下： （一）公司依法运作情况 2 一、2024 年度监事会会议召开情况 2024 年度，公司监事会认真履行工作职责，审慎行使职权，共召开了 7 次 会议，全体监事均出席了会议，不存在缺席会议的情况，对提交至监事会审议的 议案未提出异议。监事会会议的通知、召集、召开和表决程序符合《公司法》等 相关法律法规和《公司章程》《监事会议事规则》的有关规定 ...

深圳华大基因股份有限公司 关于 2025 年度为子公司提供担保额度预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司）于 2025 年 4 月 24 日召开第四届 董事会第五次会议、第四届监事会第五次会议，分别审议通过了《关于 2025 年度为 子公司提供担保额度预计的议案》，本议案在公司董事会审议权限范围内，无需提交 公司股东会审议。现将具体情况公告如下： 一、担保情况概述 证券代码：300676 证券简称：华大基因 公告编号：2025-024 （一）为满足子公司日常经营和业务发展资金需要，公司拟在 2025 年度为公司 合并报表范围内的部分子公司向银行等金融机构申请综合授信（用信品种包括但不 限于办理流动资金贷款、项目贷款、承兑汇票、信用证、保函、票据贴现、保理、出 口押汇、外汇远期结售汇以及衍生产品等相关业务）及日常经营需要（包括但不限于 履约担保、产品质量担保）时提供担保，提供担保的形式包括但不限于信用担保(含 一般保证、连带责任保证等)、抵押担保、质押担保或多种担保方式相结合等形式， 预计担保额度不超过 ...

深圳华大基因股份有限公司 2024 年度内部控制评价报告 深圳华大基因股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称企业内部控制规范体系），结合深圳华大基因股份有限公司（以下 简称公司）内部控制制度和评价办法，在内部控制日常监督和专项监督的基础上， 我们对公司截至 2024 年 12 月 31 日（内部控制评价报告基准日）的内部控制 有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，在公司范围内建立健全和有效实施内部 控制，客观公正地评价其有效性，并如实披露内部控制评价报告是公司董事会的 责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织领导企业 内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本 报告内容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、 准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在固有局限性，故仅能对实现上述目标提供合理保证。此外，由于 ...